Activity Overview
This educational activity is an archive of the live presentation held on May 31, 2026.
For more information about this educational activity, the faculty,
and disclosures, please click here.
Target Audience
This
educational activity is directed toward medical oncologists, nurse
practitioners, physician assistants, nurses, pharmacists, and other health care
providers involved in the treatment and management of lung, breast, genitourinary,
and gynecologic cancer.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Evaluate clinical trial data for approved and investigational antibody-drug conjugates (ADCs) and bispecific antibodies across lung, breast, endometrial, and prostate cancers
- Compare mechanisms of action, target biology, and payload platforms across ADC and bispecific antibody classes to inform cross-tumor treatment decisions
- Develop biomarker-informed treatment selection and sequencing strategies for ADCs and bispecifics, integrating patient-specific factors and available evidence
- Anticipate shared and class-specific toxicities of ADCs and bispecific antibodies to guide monitoring and management across clinical settings
William J. Gradishar, MD, FASCO, FACP
Betsy Bramsen Professor of
Breast Oncology and Professor of Medicine
Chief, Division of Hematology/Oncology
Feinberg School of Medicine at Northwestern University
Chicago, IL
Disclosures: Consultant: Ambryx, AstraZeneca, Carrick, Daiichi Sankyo, Genentech-Roche, Gilead Sciences, Johnson & Johnson, Lilly, Menarini-Stemline, Merck, Novartis, Pfizer, Totus, Veracyte; DMC: Alliance Foundation Trials (AFT), Genentech, IBCSG, Lilly, Pfizer/Seagen
Rebecca Arend, MD, MSPH
Associate Director of
Clinical Research
O’Neal Comprehensive Cancer Center
Division of Gynecology Oncology
UAB Medicine
Birmingham, AL
Disclosures: Rebecca Arend, MD, MSPH has no relevant financial relationships with ineligible companies.
Aaron Lisberg, MD
Assistant Professor of Clinical Medicine
University of California, Los Angeles
Los Angeles, CA
Disclosures: Advisor, Consultant, Fee for Service Recipient: AbbVie, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, BristolMyers Squibb, Daiichi Sankyo, Eli Lilly, G1 Therapeutics, Gilead Sciences, GSK, IQVIA, Janssen Oncology, Jazz Pharmaceuticals, Leica Biosystems, Molecular Axiom, MorphoSys, Novartis, Novocure, Nuvation Bio, Oncocyte, Pfizer, Regeneron, Sanofi, Whitehawk Therapeutics; Grant/Research Funding: AstraZeneca, BioNTech, Calithera Biosciences, Daiichi Sankyo, Dracen Pharmaceuticals, Duality Biologics, eFFECTOR Therapeutics, Seagen (Pfizer), WindMIL; Ownership Interests: Boston Scientific
Ulka Vaishampayan, MD, FASCO
Beverly Mitchell Research Professor of Oncology
Co-Leader of Translational Clinical Research Program
University of Michigan Rogel Cancer Center
Ann Arbor, MI
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Bayer, BMS, Janssen, Merck, Novartis, Pfizer; Grant/Research Funding: Merck
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
